CagriSema vs. Tirzepatide: What the REIMAGINE 5 Trial Really Shows

The 30-second answer

CagriSema is Novo Nordisk's next-generation weight-loss injection. It combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, a long-acting medication that mimics the pancreatic hormone amylin. On September 21, 2026, at its Capital Markets Day, Novo released two new Phase 3 results (Novo Nordisk).

The headline is that a low dose of CagriSema produced more weight loss than a low dose of tirzepatide (Mounjaro, Zepbound) in people with type 2 diabetes. That is a real result, and it matters for people who do best on lower doses. It is not the same as saying CagriSema is stronger than tirzepatide overall. Here is how to read it.

What CagriSema is

CagriSema is a once-weekly injection that pairs two hormone signals:

• Semaglutide activates the GLP-1 receptor, slowing digestion, reducing appetite, and improving blood sugar control.
• Cagrilintide is a long-acting amylin receptor agonist. Amylin is released alongside insulin after meals and helps signal fullness.

Novo is studying CagriSema for weight management in its REDEFINE program and for type 2 diabetes in its REIMAGINE program. The company filed for FDA approval for weight management in December 2025 (Novo Nordisk). For a deeper explanation of amylin, see our CagriSema and amylin guide.

REIMAGINE 5: CagriSema vs. tirzepatide in type 2 diabetes

Results

Source: Novo Nordisk press release. Results are based on the efficacy estimand, which estimates the effect if everyone stayed on treatment.

Novo's chief scientific officer, Martin Holst Lange, said that "with only 1.0 mg/1.0 mg, CagriSema shows superior weight loss versus tirzepatide 5 mg as well as strong results across obesity and type 2 diabetes."

The dose question

This is the part of the story most headlines skip. In REIMAGINE 5, both medications were tested at low doses:

• CagriSema 1.0 mg/1.0 mg is below the 2.4 mg/2.4 mg dose Novo has studied most heavily in obesity.
• Tirzepatide 5 mg is the lowest maintenance dose. Tirzepatide is approved at up to 15 mg weekly.

So REIMAGINE 5 answers a specific question: at lower doses, which medication helps people with type 2 diabetes lose more weight? It does not answer which medication is more powerful at full strength.

That second question was tested earlier. According to Reuters, CagriSema fell short of Lilly's high-dose tirzepatide in a head-to-head trial in February 2026, though CagriSema still produced an average weight reduction of 23% over 84 weeks (Reuters). BMO analyst Evan Seigerman called the new low-dose data encouraging but said it was less impactful because tirzepatide had already been proven superior to higher doses of CagriSema in obesity (Reuters).

Why low-dose results still matter

Novo's argument is that many patients never reach or stay on the highest dose of any GLP-1 medication. Side effects, cost, and personal preference all push people toward lower doses. In its release, Novo said treatment decisions are often individualized and that "not all patients receive or remain on the highest available dose of current therapies."

That is a fair point. If you are someone who gets significant nausea at higher doses, a medication that does more at a low dose could be appealing. Our guide to managing GLP-1 side effects covers why dose tolerance varies so much from person to person.

REDEFINE 9: 21% weight loss on the low dose

The second trial released on September 21 tested CagriSema in adults with overweight or obesity, alongside a reduced-calorie diet and increased physical activity.

Source: Novo Nordisk. Results for the 1.7/1.7 mg dose were not included in the announcement.

A 21% average loss on a reduced dose is a strong number, roughly in the range of what high-dose tirzepatide produced in its main obesity trials. It is worth keeping in mind that trial populations and designs differ, so cross-trial comparisons are rough.

Safety

Novo described CagriSema as well tolerated in both trials, with a safety profile consistent with previous studies. The press release did not include specific side-effect rates or discontinuation numbers, so we cannot yet compare tolerability with tirzepatide in REIMAGINE 5. Earlier CagriSema trials showed the typical GLP-1 pattern: mostly gastrointestinal side effects, especially during dose increases.

We will update this article when the full REIMAGINE 5 data are presented or published.

How CagriSema compares with what is coming

CagriSema is not the only combination medication in development. Within ten days of Novo's announcement, Lilly presented Phase 2 data for EloraTZP, which pairs its own amylin medication with tirzepatide, and full Phase 3 results for retatrutide in type 2 diabetes.

These are separate trials with different lengths and populations, so they are not direct comparisons. See our coverage of EloraTZP vs. Zepbound and the full TRIUMPH-2 results for details.

Amylin: why everyone is adding it

CagriSema is part of a broader shift. For the past several years, the weight-loss medication story was about GLP-1 and, with tirzepatide, GIP. Now nearly every major drugmaker is testing amylin-based medications, either alone or in combination.

Amylin is a hormone made in the pancreas alongside insulin. After you eat, it helps slow stomach emptying and signals the brain that you are full. Because it works through a different receptor than GLP-1, researchers expect the two signals to add together rather than overlap. Novo's Martin Holst Lange said the new data "add to the growing evidence for amylin biology" (Novo Nordisk).

There are a few practical reasons this matters for patients:

• Lower doses of each component. If two signals add together, each medication may be effective at a lower dose, which could mean fewer side effects for some people. REIMAGINE 5 tested exactly that idea.
• More options when one medication stalls. People who plateau on a GLP-1 may eventually have combinations to step up to, rather than simply increasing the dose of one medication. Our guide to GLP-1 weight-loss plateaus covers what to try in the meantime.

Questions to ask your prescriber

If CagriSema is approved and you are considering it, these questions can help you have a productive conversation:

1. Based on my current results and side effects, would I be likely to benefit from a combination medication, or should I stay on what I have?
2. Would my insurance cover CagriSema, and what would the cost difference be compared with my current medication?
3. If I switch, how would we handle the transition: do I start at a low dose again, and how long until I see results?
4. Since I have type 2 diabetes (if you do), would CagriSema be prescribed for weight management or diabetes, and does that affect coverage?
5. What side effects should I watch for in the first few months?

Bringing a few weeks of your own weight, dose, and side-effect history to that appointment makes the conversation far more useful than relying on memory.

When could CagriSema be available?

• FDA decision: expected in the fourth quarter of 2026 for weight management (Reuters).
• Launch: Novo is targeting early 2027.
• Type 2 diabetes: REIMAGINE trials support a separate diabetes indication, which would require its own regulatory submission.
• Price and coverage: not yet announced. Expect coverage to follow the same patterns as Wegovy and Zepbound, which vary widely by plan. Our cost estimator can help you plan for current options.

What this means for you

• If you are on tirzepatide and doing well, there is no reason to change. These results do not show CagriSema is better than tirzepatide at the doses most people use for weight loss.
• If you struggle with side effects at higher doses, CagriSema's low-dose performance could make it worth discussing with your prescriber once it is approved.
• If you have type 2 diabetes, both medications improved A1C by a similar amount. The decision will likely come down to weight goals, tolerability, and coverage.
• Do not buy CagriSema online. It is not approved, and any product sold under that name is not the trial medication.

Frequently asked questions

Is CagriSema better than tirzepatide?

Not overall. In REIMAGINE 5, low-dose CagriSema (1.0/1.0 mg) beat low-dose tirzepatide (5 mg) on weight loss in type 2 diabetes, 12.4% vs. 9.1%. But in an earlier head-to-head obesity trial, high-dose tirzepatide outperformed CagriSema.

What is CagriSema?

CagriSema is an investigational once-weekly injection from Novo Nordisk that combines semaglutide (a GLP-1 receptor agonist) with cagrilintide (a long-acting amylin receptor agonist).

When will CagriSema be approved?

Novo filed for FDA approval for weight management in December 2025. A decision is expected in the fourth quarter of 2026, and Novo is targeting a launch early in 2027.

How much weight did people lose on CagriSema in REDEFINE 9?

Adults with overweight or obesity on CagriSema 1.0/1.0 mg lost an average of 21.0% of body weight at 68 weeks, compared with 2.0% on placebo.

Should I switch from Zepbound or Mounjaro to CagriSema?

Not based on these results. CagriSema is not yet approved, and the new trial compared it only with the lowest tirzepatide maintenance dose. Discuss any future switch with your prescriber.

The bottom line

REIMAGINE 5 is a genuine win for CagriSema at low doses, and it strengthens the case for amylin-based combinations. It does not make CagriSema the strongest weight-loss medication. If it is approved later this year, it will become one more good option, especially for people who do best on lower doses.

Related reading

• CagriSema and amylin: the complete guide
• Mounjaro vs. Zepbound
• Next-generation weight loss medications
• EloraTZP vs. Zepbound
• Retatrutide vs. tirzepatide

Sources

• Novo Nordisk: CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5
• Reuters: Novo says its next-gen obesity drug tops Lilly rival
• Reuters: Experimental Lilly combination drug tops Zepbound

Educational content written by Rolando Valenzuela, founder of GLPTree. Not medical advice. Talk to your prescriber before starting, stopping, or switching any medication.